Sugi Predict

Sugi Predict / Compounds / SCHEMBL19949262

SCHEMBL19949262

SCHEMBL19949262

Cc1cc(C(=O)CCCNC(=O)O)cc(F)c1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.37
▸ HDAC6 Q9UBN7 3/20 0.35
▸ HDAC1 Q13547 5/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ TMEM97 Q5BJF2 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ FABP4 P15090 1/20 0.33
▸ HTR7 P34969 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ HDAC8 Q9BY41 2/20 0.32
▸ HDAC3 O15379 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29746426 0.84 TDP1 (0.41) CYP1A2CYP2C19ALDH1A1SIGMAR1MEN1
SCHEMBL19948710 0.84 TDP1 (0.41) CYP1A2CYP2C19ALDH1A1SIGMAR1MEN1
SCHEMBL26987541 0.75 MAPK1 (0.41) HDAC6HDAC1NPC1RAB9AHDAC8
SCHEMBL31700656 0.73 TPMT (0.45) TSHRHDAC6HDAC1CYP1A2ALDH1A1
SCHEMBL24933146 0.73 TDP1 (0.46) TSHRCYP1A2CYP2C19ALDH1A1SIGMAR1
SCHEMBL2042619 0.71 HDAC1 (0.58) HDAC6HDAC1ALDH1A1MAPTNPC1
SCHEMBL26987820 0.70 TMEM97 (0.48) HDAC6ALDH1A1TMEM97SIGMAR1NPC1
SCHEMBL18854469 0.70 HDAC1 (0.42) TSHRHDAC6HDAC1ALDH1A1MAPT
SCHEMBL22168072 0.69 KDM4E (0.48) HDAC6HDAC1ALDH1A1MAPTLMNA
SCHEMBL31701851 0.69 HDAC1 (0.41) TSHRHDAC6HDAC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 — — US disclosed
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2023-01-03 — — US disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 — — EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 — — US disclosed
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-02 — — US disclosed
US-11014929-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-05-25 — — US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 — — US disclosed
US-20200172545-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-06-04 — — US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 — — US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 — — US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 — — US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 — — US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
WO-2018049152-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 — — WO disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172545-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, MAPKAPK5 TSHR 4773/4885HDAC6 935/4885HDAC1 538/4885
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 TSHR 4765/4885HDAC6 1588/4885HDAC1 896/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-11014929-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, MAPKAPK5 TSHR 4773/4885HDAC6 935/4885HDAC1 538/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-11542265-B2 Pyrazolopyrimidine compounds and uses thereof PDXK, PCK1, PDK2 TSHR 4765/4885HDAC6 1588/4885HDAC1 896/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 TSHR 4733/4885HDAC6 1661/4885HDAC1 951/4885
US-20210371425-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 TSHR 4765/4885HDAC6 1588/4885HDAC1 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.